Georgia recalls
3792 federal recalls on file affecting Georgia - 717 Georgia-specific plus 3075 nationwide. Sourced from CPSC, FDA, USDA, and NHTSA.
- 2026-02-11FDA-DeviceVantiveClass IINationwideStop using Vantive Prismaflex M100 dialyzer sets
There is a potential dislodgement of the Prismaflex Set deaeration chamber from the Prismaflex Control Unit.
- 2026-02-11FDA-DeviceVantiveClass IINationwideCheck your OXIRIS dialyzer set immediately
There is a potential dislodgement of the Prismaflex Set deaeration chamber from the Prismaflex Control Unit.
- 2026-02-11FDA-DeviceVantiveClass IINationwideCheck your Vantive Prismaflex ST150 dialyzer set
There is a potential dislodgement of the Prismaflex Set deaeration chamber from the Prismaflex Control Unit.
- 2026-02-11FDA-DeviceVantiveClass IINationwideStop using affected Vantive Prismaflex ST100 sets
There is a potential dislodgement of the Prismaflex Set deaeration chamber from the Prismaflex Control Unit.
- 2026-02-11FDA-DeviceOlympusClass IINationwideStop using Olympus electrosurgical knife KD-645L
A deterioration of the cutting knife, including overheating and burning, can contribute to tip breakage during use.
- 2026-02-11FDA-DeviceOlympusClass IINationwideStop using Olympus KD-640L electrosurgical knives
A deterioration of the cutting knife, including overheating and burning, can contribute to tip breakage during use.
- 2026-02-11FDA-DeviceBeckman CoulterClass IINationwideStop using recalled Beckman Coulter diluent lots
Due to specific lots of diluents contributing to elevated platelet Daily Checks background counts cycle with use with analyzers.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideCheck your AXIOS Stent lot number immediately
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideContact your doctor about AXIOS Stent
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideCheck HOT AXIOS Stent lot numbers immediately
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideContact your doctor about Boston Scientific AXIOS Stent
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideContact your doctor about AXIOS Stent recall
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-DeviceBoston ScientificClass INationwideStop using Boston Scientific AXIOS Stent
Increased reports of stent deployment and expansion issues. The most common outcome reasonably foreseeable resulting from difficulty deploying the stent is prolongation of the procedure to exchange the device for a new one. The most serious reasonably foreseeable outcome in cases where the first flange is unable to deploy or expand would be a cascade of events resulting in additional intervention, either endoscopic or surgical, to remove the stent and close the puncture site.
- 2026-02-11FDA-FoodB.C. Williams Bakery ServiceClass INationwideStop using B.C. Williams Swiss Chocolate Cake Mix
Undeclared Milk Allergen
- 2026-02-11FDA-FoodB.C. Williams Bakery ServiceClass INationwideStop using B.C. Williams Bakery Bread and Roll Mix
Undeclared Milk Allergen
- 2026-02-11FDA-FoodB.C. Williams Bakery ServiceClass INationwideStop using B.C. Williams Spice Cake Mix
Undeclared Milk Allergen
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam strawberry sea moss gel
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam sea moss gel
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam Sea Moss Gel Superfood
potential Clostridium botulinum contamination
- 2026-02-11FDA-FoodDiva FamClass IINationwideStop using Diva Fam mango sea moss gel
potential Clostridium botulinum contamination
Get notified about new Georgia recalls
Free weekly digest. Add Georgia to your profile to filter alerts to your state.
Get the Sunday Brief